Adaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvements
Q4 2024 Management View CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 ...